About Us

We want to do more than just treat monogenic CNS disease. We want to eradicate it.

Our Story

Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations. The team’s primary focus is advancing our lead clinical program in Rett syndrome, and our pipeline of CNS programs offers additional development opportunities.

Our leaders include pioneers in gene therapy and rare diseases, having been responsible for the discovery, development and commercialization of the first U.S. FDA approved gene therapy to treat a monogenic CNS disorder. This experience has led to strong relationships with key stakeholders that are imperative to future drug development.

Our team of experienced scientists, clinicians and patient advocates are driven to develop treatments that have the potential to dramatically improve the lives of patients and their families. This shared passion and drive is what makes us Taysha.

Our Mission

Our mission is to eradicate monogenic diseases of the central nervous system.

Our Defining Values

At our core, we embody shared values that represent our identity and guide our behaviors, decisions and actions. We believe living out these values will support our efforts to deliver transformative treatments to patients and families.


We are thoughtful, transparent and strive to do what is right, always staying true to who we are and what we stand for.


We deliver on our commitments and hold ourselves responsible for our actions and decisions.


We work together and apply our collective knowledge and expertise to achieve breakthroughs in gene therapy.

Our Team

We’ve assembled the experts.

Our team is comprised of some of the most accomplished and knowledgeable gene therapy and CNS disease experts. Together – armed with our unrelenting, patient-first focus – we are working to bring new treatments to life.

Leadership Team

Sean Nolan

Chief Executive Officer and Board Chairman

Sukumar Nagendran, M.D.

President and Head of Research and Development

Meredith Schultz, M.D., M.S.

Chief Medical Officer

Kamran Alam

Chief Financial Officer

Emily McGinnis

Chief Patient and External Affairs Officer, and Endpoint and Outcome Development Lead

Rumana Haque-Ahmed

Chief Regulatory Officer

Fred Porter, Ph.D.

Chief of Staff and Technical Operations Officer

Sean McAuliffe

Chief Business Officer

Tracy M. Porter, M.Ed., SPHR

Chief People Officer

Board of Directors

Sean Nolan

Chief Executive Officer and Board Chairman

Sukumar Nagendran, M.D.

President and Head of Research and Development

Laura Sepp-Lorenzino, Ph.D.

Chief Scientific Officer, Intellia Therapeutics

Alison Long, M.D., Ph.D.

Chief Medical Officer, Flightpath Biosciences

Phillip Donenberg, CPA

Former Chief Financial Officer, AveXis

Sean Stalfort

President, PBM Capital

Independent Scientific Advisory Board

Professor Dr. med. Benedikt Schoser, FEAN

David P. Dimmock, M.D.

Gerald S. Lipshutz, M.D., M.S.

Wendy K. Chung, M.D., Ph.D.

Deborah Bilder, M.D.

Chief Advisors

Berge Minassian, M.D.

Chief Medical Advisor
UT Southwestern Gene Therapy Program

Steven Gray, Ph.D.

Chief Scientific Advisor
UT Southwestern Gene Therapy Program

Board of Directors

Chief Advisors